My takeaways from the Proactive Video..The theme is focus and cash management IMO..
I mentioned after the CD12 trial results I would not continue it with another trial in the US I would shut it down because the focus needed to be on managing cash and focus on what paths had a clearer path to revenue . I am glad that was the messaging as I understood it.
Focusing on other countries with larger issues with Covid and a much larger population of sick patients makes sense . I posted on another board this morning before the video, don't be surprised if India, Chiral, and Cytodyn arent talking. Well they are and they are going to move forward in a country of over a billion people. The FDA in Philippines getting lit up by their Congress also tells me that an EUA type agreement is coming soon. Brazil trial to start in 3 weeks, etc. all together these populations of the combined countries dwarf the 330 millions in the US and are more apt to approve the drug quicker, at least in EUA form.
On LH I believe they will end up going to a phase3 trial which will be large . In order to do that , it will take a lot of capital to execute the trial so either a partner or, with the new loan, Cytodyn cash will be able to move that forward
I was also encouraged that Cytodyn will be asking for revenue regarding the continual use of Leronlimab by patients who have needing the drug for their HIV treatments . No more free-bees..We pretty much got an admission that Mahoob was removed as NP spoke about people coming and going etc. Mahoob didnt hit his objectives for delivering the BLA HIV so we move on .
Anyway, some are frustrated by the video;some are happy. I see it as a company maturing in how they go about their business.. focusing on trials that make the most sense.. deciding the FDA wont play ball with any small drug company who is trying to get into the ICUs for Covid ; going overseas where the drug is most needed for very sick populations ; and stopping the free distribution of Leronlimab on the HIV side of the house. And most important , focusing the cash on trials with the best probability to produce a return this year and in 2022
I mentioned after the CD12 trial results I would not continue it with another trial in the US I would shut it down because the focus needed to be on managing cash and focus on what paths had a clearer path to revenue . I am glad that was the messaging as I understood it.
Focusing on other countries with larger issues with Covid and a much larger population of sick patients makes sense . I posted on another board this morning before the video, don't be surprised if India, Chiral, and Cytodyn arent talking. Well they are and they are going to move forward in a country of over a billion people. The FDA in Philippines getting lit up by their Congress also tells me that an EUA type agreement is coming soon. Brazil trial to start in 3 weeks, etc. all together these populations of the combined countries dwarf the 330 millions in the US and are more apt to approve the drug quicker, at least in EUA form.
On LH I believe they will end up going to a phase3 trial which will be large . In order to do that , it will take a lot of capital to execute the trial so either a partner or, with the new loan, Cytodyn cash will be able to move that forward
I was also encouraged that Cytodyn will be asking for revenue regarding the continual use of Leronlimab by patients who have needing the drug for their HIV treatments . No more free-bees..We pretty much got an admission that Mahoob was removed as NP spoke about people coming and going etc. Mahoob didnt hit his objectives for delivering the BLA HIV so we move on .
Anyway, some are frustrated by the video;some are happy. I see it as a company maturing in how they go about their business.. focusing on trials that make the most sense.. deciding the FDA wont play ball with any small drug company who is trying to get into the ICUs for Covid ; going overseas where the drug is most needed for very sick populations ; and stopping the free distribution of Leronlimab on the HIV side of the house. And most important , focusing the cash on trials with the best probability to produce a return this year and in 2022
14
